Recurrent targets of aberrant somatic hypermutation in lymphoma

Alireza Hadj Khodabakhshi; Ryan D Morin; Anthony P Fejes; Andrew J Mungall; Karen L Mungall; Madison Bolger-Munro; Nathalie A Johnson; Joseph M Connors; Randy D Gascoyne; Marco A Marra; Inanc Birol; Steven JM Jones

doi:10.18632/oncotarget.653

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Recurrent targets of aberrant somatic hypermutation in lymphoma

Alireza Hadj Khodabakhshi, Ryan D Morin, Anthony P Fejes, Andrew J Mungall, Karen L Mungall, Madison Bolger-Munro, Nathalie A Johnson, Joseph M Connors, Randy D Gascoyne, Marco A Marra, Inanc Birol and Steven JM Jones _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2012; 3:1308-1319. https://doi.org/10.18632/oncotarget.653

Metrics: PDF 4794 views | HTML 4902 views | ?

Abstract

Alireza Hadj Khodabakhshi1,Ryan D. Morin1, Anthony P. Fejes1, Andrew J. Mungall1, Karen L. Mungall1, Madison Bolger-Munro1, Nathalie A. Johnson2, Joseph M. Connors2, Randy D. Gascoyne2,3, Marco A. Marra1,4, Inanc Birol1, Steven J. M. Jones1,4,5

1 Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada

2 Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada

3 Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada

4 Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada

5 Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada

Correspondence:

Steven J. M. Jones, email:

Keywords: Aberrant somatic hypermutation, Genome wide study, Diffuse large B-cell lymphoma, Genomic rearrangements

Received: September 13, 2012, Accepted: October 10, 2012, Published: October 12, 2012

Abstract

Somatic hypermutation (SHM) in the variable region of immunoglobulin genes (IGV) naturally occurs in a narrow window of B cell development to provide high-affinity antibodies. However, SHM can also aberrantly target proto-oncogenes and cause genome instability. The role of aberrant SHM (aSHM) has been widely studied in various non-Hodgkin’s lymphoma particularly in diffuse large B-cell lymphoma (DLBCL). Although, it has been speculated that aSHM targets a wide range of genome loci so far only twelve genes have been identified as targets of aSHM through the targeted sequencing of selected genes. A genome-wide study aiming at identifying a comprehensive set of aSHM targets recurrently occurring in DLBCL has not been previously undertaken. Here, we present a comprehensive assessment of the somatic hypermutated genes in DLBCL identified through an analysis of genomic and transcriptome data derived from 40 DLBCL patients. Our analysis verifies that there are indeed many genes that are recurrently affected by aSHM. In particular, we have identified 32 novel targets that show same or higher level of aSHM activity than genes previously reported. Amongst these novel targets, 22 genes showed a significant correlation between mRNA abundance and aSHM.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 653

Publication Alerts

Research Papers:

Recurrent targets of aberrant somatic hypermutation in lymphoma

Abstract